Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Trial of BI 655130 in Active Ulcerative Colitis
2017-000100-20Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of spesolimab in autoimmune colitis, sponsored by Boehringer Ingelheim. Primary endpoint: Total number of deregulated genes. Started Mar 2017; status: completed.
02
Drugs
spesolimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-000100-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000100-20.